Cargando…
NRF2 Is One of the Players Involved in Bone Marrow Mediated Drug Resistance in Multiple Myeloma
Multiple myeloma with clonal plasma expansion in bone marrow is the second most common hematologic malignancy in the world. Though the improvement of outcomes from the achievement of novel agents in recent decades, the disease progresses and leads to death eventually due to the elusive nature of mye...
Autores principales: | Yen, Chia-Hung, Hsiao, Hui-Hua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6274683/ https://www.ncbi.nlm.nih.gov/pubmed/30405034 http://dx.doi.org/10.3390/ijms19113503 |
Ejemplares similares
-
Pathogenic Mechanisms of Myeloma Bone Disease and Possible Roles for NRF2
por: Yen, Chia-Hung, et al.
Publicado: (2020) -
Management of Myeloma Bone Lesions
por: Du, Jeng-Shiun, et al.
Publicado: (2021) -
Bone Marrow Stromal Cells-Induced Drug Resistance in Multiple Myeloma
por: Ria, Roberto, et al.
Publicado: (2020) -
Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche
por: Solimando, Antonio Giovanni, et al.
Publicado: (2022) -
Bone Marrow Microenvironment in Multiple Myeloma Progression
por: Manier, S., et al.
Publicado: (2012)